Related Experiment Video
Updated: Jun 22, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Lipid changes associated with antiretroviral therapy: results differ by reporting approach
1Division of Endocrinology, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA. lakey001@mc.duke.edu
Current HIV Research
|June 19, 2009
Summary
Lipid reporting in antiretroviral treatment (ART) studies lacks consistency. Standardizing reporting with guidelines like NCEP and the Framingham model can improve clinical data utility.
Area of Science:
- Clinical Trials
- Pharmacology
- Cardiovascular Health
Background:
- Lipid reporting in antiretroviral treatment (ART) studies is inconsistent.
- Existing ART trial data lacks comparability due to varied lipid reporting methods.
Purpose of the Study:
- To evaluate the consistency and comparability of lipid reporting across ART studies.
- To highlight the impact of different lipid reporting methodologies on study outcomes.
Main Methods:
- Analysis of 25 ART trials cited in DHHS Guidelines.
- Comparison of lipid reporting methods including graded toxicities, median/mean values, NCEP Guidelines, and Framingham risk-prediction model.
Main Results:
- Most trials (n=20) reported lipids as graded laboratory toxicities.
- Reporting as proportion not at goal per NCEP revealed higher rates (23% triglycerides, 39% HDL).
- Framingham model predicted elevated 10-year cardiovascular disease risk in 12% of patients.
Conclusions:
- Significant variability exists in lipid reporting across ART trials.
- Standardized reporting using NCEP Guidelines and Framingham risk model is recommended for improved clinical data.
- Consistent lipid reporting can enhance clinical decision-making for patients on ART.
